MGC

InfuSystem Holdings, Inc. (NYSE MKT: INFU) ("InfuSystem" or the "Company"), a
leading national provider of infusion pumps and related services for the
healthcare industry in the United States, today announced that the InfuSystem
Board of Directors has nominated Gregg O. Lehman, Ph.D., 66, Chief Executive
Officer and President of MGC Diagnostics Corporation (NASDAQ: MGCD) ("MGC"), a
global medical technology company, to stand for election to the Board at the
2014 Annual Meeting of Shareholders. 


"We are pleased that Dr. Lehman has agreed to join our Board," said Ryan Morris,
InfuSystem's Executive Chairman. "He offers an extensive range of
healthcare-related experience that we can draw upon to deliver increased value
to both patients and shareholders. Further, his demonstrated record of success
growing value as an entrepreneur is consistent with the business culture we have
instilled across the Company."


Dr. Lehman's election would increase the number of InfuSystem Board members to
six. All incumbent Directors are also seeking one-year terms. InfuSystem's
Annual Meeting of Shareholders is scheduled to be held on May 8, 2014 at the
Company's headquarters in Madison Heights, MI.


Mr. Morris added that the transformative business and financial progress
InfuSystem has achieved now enables the Company to attract the highly qualified,
experienced healthcare professionals needed to spur future growth. "This is
especially gratifying given the condition of the Company when our activist-led
team gained control two years ago. We have created a far more unified
organization and successfully implemented governance best practices. Further, we
have set up incentives for shareholder-alignment among employees at all levels.
Appropriately, I plan to step down from my executive responsibilities following
the shareholder meeting and assume the title of Board Chairman." 


Prior to joining MGC in 2011, Dr. Lehman served as President, Chief Executive
Officer and a Director of Health Fitness Corporation, a fitness-center
management company, for five years. In a long career, he has also held numerous
senior-level executive and governance positions in the medical and education
industries including CEO of Inspiris, Inc., a health care management company;
CEO of Gordon Health Solutions, Inc., which provides lifestyle and disease
management programs to employers and health plans; CEO of the National Business
Coalition on Health (NBCH) in Washington, D.C.; and President of Taylor
University in Indiana. Additionally, he has also authored numerous articles on
the issue of patient safety. 


"I look forward to working with Ryan and the entire InfuSystem Board, especially
CEO Eric Steen, who has done so much to revitalize the strategic direction and
operational performance of the Company in the past year," Dr. Lehman commented.


About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related
services to hospitals, oncology practices and other alternate site healthcare
providers. Headquartered in Madison Heights, Michigan, the Company delivers
local, field-based customer support and also operates Centers of Excellence in
Michigan, Kansas, California, Texas and Ontario, Canada. The Company's stock is
traded on the NYSE MKT under the symbol INFU.


Forward-Looking Statements
Certain statements contained in this release are forward-looking statements and
are based on future expectations, plans and prospects for InfuSystem Holdings,
Inc.'s ("InfuSystem," "INFU," "the Company," "We") business and operations that
involve a number of risks and uncertainties. The Company's outlook for 2014 and
other forward-looking statements in this release are made as of April 9, 2014,
and the Company disclaims any duty to supplement, update or revise such
statements on a going-forward basis, whether as a result of subsequent
developments, changed expectations or otherwise. In connection with the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995, the
Company is identifying certain factors that could cause actual results to
differ, perhaps materially, from those indicated by these forward-looking
statements. Those factors, risks and uncertainties include, but are not limited
to, potential changes in overall healthcare reimbursement -- including CMS
competitive bidding, sequestration, concentration of customers, increased focus
on early detection of cancer, competitive treatments, dependency on Medicare
Supplier Number, availability of chemotherapy drugs, global financial
conditions, changes and enforcement of state and federal laws, natural forces,
competition, dependency on suppliers, risks in acquisitions & joint ventures, US
Healthcare Reform, relationships with healthcare professionals and
organizations, technological changes related to infusion therapy, dependency on
websites and intellectual property, the ability of the Company to successfully
integrate acquired businesses, dependency on key personnel, dependency on
banking relations and covenants, and other risks associated with our common
stock, as well as any other litigation to which the Company may be subject from
time to time; and other risk factors as discussed in the Company's annual report
on Form 10-K for the year ended December 31, 2013 and in other filings made by
the Company from time to time with the Securities and Exchange Commission.


Additional information about InfuSystem Holdings, Inc. is available at
www.infusystem.com.



FOR FURTHER INFORMATION PLEASE CONTACT: 

CONTACT: 
Rob Swadosh
The Dilenschneider Group
212-922-0900

Midasco Capital Corp. (TSXV:MGC)
Historical Stock Chart
From May 2024 to Jun 2024

Midasco Capital Corp. (TSXV:MGC)
Historical Stock Chart
From Jun 2023 to Jun 2024